Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The US FDA’s Advisory Committee Drought

Aug 05 2021

• By Michael McCaughan

• Source: Alamy

Related Content

US FDA’s Breakneck Approval Pace Clashes With Advisory Committee Mandate

Jan 09 2020

US FDA’s Novel Approval Count Hits 32 In First Half Of 2021, With More Than 40 Goal Dates Ahead

Jul 06 2021

FDA’s Mismanaged Aduhelm Review: What Went Wrong

Jul 07 2021

Recent And Upcoming FDA Advisory Committee Meetings

Jul 30 2021

Gene Therapy AAV Vector Toxicities Get US FDA's Attention

Jul 26 2021

US FDA Advisory Committees Could Get Revamp With A Focus On Science Over Emotion

Jun 16 2021

Aduhelm Approval Firestorm Raises Question: What Are US FDA Advisory Committees For, Anyway?

Jun 11 2021

Roxadustat Rejection Has Lessons For Other Sponsors

Jul 23 2021

Related Companies

AstraZeneca PLC

FibroGen, Inc.

Takeda Pharmaceutical Co. Ltd.

Eli Lilly and Company

Innovent Biologics, Inc.

Reata Pharmaceuticals, Inc.

Merck & Co., Inc.

Biogen, Inc.

Eisai Co., Ltd.

Additional Topics

United States Advisory Committees Drug Review Regulation BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window